These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38319706)

  • 1. Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma.
    Wu B; Zhang X; Feng N; Guo Z; Gao L; Wan Z; Zhang W
    Aging (Albany NY); 2024 Feb; 16(3):2273-2298. PubMed ID: 38319706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel anoikis-related gene signature to predict prognosis and tumor microenvironment in lung adenocarcinoma.
    Diao X; Guo C; Li S
    Thorac Cancer; 2023 Jan; 14(3):320-330. PubMed ID: 36507553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and validation of a prognostic signature based on anoikis-related lncRNAs in lung adenocarcinoma.
    Dong X; Shao C; Xu S; Tu J; Xu W; Chen D; Tang Y
    Aging (Albany NY); 2024 Jun; 16(11):9899-9917. PubMed ID: 38850527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
    Zeng C; Yu H; Liu X; Liu Q; Jin J
    Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the prognostic value in lung adenocarcinoma based on anoikis-related genes and initial experimental validation.
    Guo W; Zhao G; Liu S; Deng T; Zhang G; Zhang B
    J Gene Med; 2023 Sep; 25(9):e3534. PubMed ID: 37259225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anoikis-related subtype and prognosis analyses based on bioinformatics, and an expression verification of ANGPTL4 based on experiments of lung adenocarcinoma.
    Shen X; Xie J; Liu S; Cai Y; Yuan S; Uehara Y; Zhu D; Zheng M
    J Thorac Dis; 2024 Aug; 16(8):5361-5378. PubMed ID: 39268091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
    Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
    Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
    You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
    Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma.
    Zhuang J; Chen Z; Chen Z; Chen J; Liu M; Xu X; Liu Y; Yang S; Hu Z; He F
    Respir Res; 2022 May; 23(1):123. PubMed ID: 35562727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value and immune landscapes of immunogenic cell death-associated lncRNAs in lung adenocarcinoma.
    Shu K; Cai C; Chen W; Ding J; Guo Z; Wei Y; Zhang W
    Sci Rep; 2023 Nov; 13(1):19151. PubMed ID: 37932413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An anoikis-related lncRNA signature is a useful tool for predicting the prognosis of patients with lung adenocarcinoma.
    Jiang X; Gao YL; Li JY; Tong YY; Meng ZY; Yang SG; Zhu CT
    Heliyon; 2023 Nov; 9(11):e22200. PubMed ID: 38053861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel signature based on autophagy-related lncRNA for prognostic prediction and candidate drugs for lung adenocarcinoma.
    Gong Z; Li Q; Li J; Xie J; Wang W
    Transl Cancer Res; 2022 Jan; 11(1):14-28. PubMed ID: 35261881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
    Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
    BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
    Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
    Front Genet; 2022; 13():838624. PubMed ID: 35928454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel anoikis-related gene signature to predict the prognosis, immune infiltration, and therapeutic outcome of lung adenocarcinoma.
    Wang Y; Xie C; Su Y
    J Thorac Dis; 2023 Mar; 15(3):1335-1352. PubMed ID: 37065587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
    Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
    BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in lung adenocarcinoma.
    Liu Y; Hu S; Teng M; Qing Y; Dong X; Chen L; Ai K
    J Gene Med; 2024 Feb; 26(1):e3610. PubMed ID: 37985130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.